PRTK News and Press, Paratek Pharmaceuticals Inc. From 05/26/21

BOSTON, May 26, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, gove...

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q1 2021 Earnings Call May 17, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q1 2021 Earnings Call Transcript

Paratek Pharmaceuticals, Inc. (PRTK) Q1 2021 Earnings Conference Call May 17, 2021 08:30 ET Company Participants Ben Strain - Vice President of Investor Relations Evan Loh - Chief Executive Officer Adam Woodrow - President & Chief Commercial Officer Randy Brenner - Chief Development &...

Paratek Pharmaceuticals (PRTK): Q1 GAAP EPS of -$0.39 misses by $0.07.Revenue of $16.43M (+107.4% Y/Y) misses by $12.3M.“With our expansion into the primary care setting now well underway, we anticipate the commercial growth of NUZYRA to continue throughout 2021. We are also encouraged...

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $13.2 Million in the First Quarter 2021; 6% Increase Over the Fourth Quarter 2020 -- BARDA has Initiated the First Procurement of NUZYRA Valued at ~$38 Million in the Second Quarter of 2021 -- NUZYRA Expansion...

BOSTON, May 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, gov...

Paratek's new broad-spectrum antibiotic Nuzyra has shown good uptake so far in the hospital setting, and the company is starting to try to break into primary care as well. Paratek has further upside potential based on its contract with BARDA for anthrax treatment and prevention, as we...

Gainers: [[TLS]] +21.3%. [[IMMP]] +13.1%. [[PRTK]] +6.5%. [[WIMI]] +3.8%. [[YY]] +3.4%.Losers: [[CRMD]] -8.9%. [[SYBX]] -5.3%. [[PRQR]] -4.7%. [[CD]] -4.6%. [[OLK]] -3.9%. For further details see: TLS, IMMP, CRMD and SYBX among after-hours movers

Today, we are circling back on antibiotic concern Paratek Pharmaceuticals after the company provided an encouraging business update. The company has done a good job of rolling out NUZYRA despite the impacts of the pandemic in 2020. We update our investment thesis on Paratek Pharma...

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q4 2020 Earnings Call Feb 24, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q4 2020 Earnings Call Transcript